UnknownPhase 2NCT03171389
POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sebastian Bauer
- Principal Investigator
- Sebastian Bauer, Prof. Dr.University Hospital, Essen
- Intervention
- Ponatinib 30 MG(drug)
- Enrollment
- 81 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (1)
- West German Cancer Center, Essen, North Rhine-Westphalia, Germany
Collaborators
Hannover Medical School · Helios Klinikum Berlin-Buch · University Hospital Tuebingen · Universitätsmedizin Mannheim · University Hospital, Aachen · Helios Klinikum Bad Saarow · WiSP GmbH
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03171389 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- RECRUITINGPHASE2NCT07434843PH 2 Pemigatinib in SDH-deficient GISTDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07406633KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line SettingKumquat Biosciences Inc.
- ENROLLING BY INVITATIONPHASE2NCT07550582Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal JunctionPeking University People's Hospital
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1, PHASE2NCT07096609Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST PatientsAsan Medical Center
- RECRUITINGPHASE2NCT07559864Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentJian Li